Recruiting
Amyotrophic lateral sclerosis
RecruitingSafety and Tolerability of Intrathecal TRCN-1023 in Adults with Amyotrophic Lateral Sclerosis (ALS) – Randomized Placebo‑Controlled Phase 1/2 Trial
Investigational
Safety and Tolerability of Intrathecal TRCN-1023 in Adults with Amyotrophic Lateral Sclerosis (ALS) – Randomized Placebo‑Controlled Phase 1/2 Trial
Investigational
- Disease:Amyotrophic lateral sclerosis
- Substances:–
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Sponsor:Trace Neuroscience Inc.


